ArticleEuropean child & adolescent psychiatry2025
Irritability in children with RASopathies, insights into emotional dysregulation and social impairment.
Article in European child & adolescent psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- RAS/MAPK pathway modulation with simvastatin in children with Noonan syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.EClinicalMedicine · 2026Article
- Subcortical shape alterations in children with Noonan syndrome spectrum: insights into genotype-phenotype associations.Cerebral cortex (New York, N.Y. : 1991) · 2025Article
- Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
RASopathies, including Noonan Syndrome (NS) and Neurofibromatosis type 1 (NF1), are developmental disorders caused by germline mutations in genes of the RAS-mitogen-activated protein kinase pathway (RAS-MAPK). This study investigates irritability, a highly prevalent transdiagnostic construct, in children with NS and NF1 and the impact of RASopathy status on the associations between irritability, emotional dysregulation-related disorders, and social impairment. The sample comprises 174 children aged 4–17 (age mean = 9.49; 98 females), including 113 children with RASopathies (NS n = 85, NF1 n = 28) and 61 age-sex-matched typically developed (TD) children. We used parent proxy questionnaires (CBCL, SRS) to assess irritability, symptoms of ADHD, defiance, anxiety/depression, and social impairment while controlling for cognitive measures (IQ). Children with RASopathies exhibited higher irritability than TD children (mean difference = 1.09; p <.001). Children with NS showed a weaker association between irritability and ADHD symptoms compared to TD children (p =.032, ηp2 = 0.03) and a stronger association between irritability and social impairment compared to both TD (p =.033, ηp2 = 0.03) and NF1 groups (p =.009, ηp2 = 0.06). We present novel and clinically significant findings showing high irritability in children with NS and NF1. Our study provides syndrome-specific results, suggesting differences in the mechanisms involved in irritability, ADHD, and social processes. In essence, children with RASopathies showed a highly irritable profile associated with ADHD symptoms and social impairment, with a significantly stronger association between irritability and social processes in NS. Our results suggest that developing prevention and treatments targeting irritability can distinctly affect the trajectories of neurodevelopmental disorders in children with NS and NF1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.